| 9.55 -0.71 (-6.92%) | 10-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 14.1 |
1-year : | 15.98 |
| Resists | First : | 12.07 |
Second : | 13.68 |
| Pivot price | 10.87 |
|||
| Supports | First : | 9.46 |
Second : | 7.87 |
| MAs | MA(5) : | 10.2 |
MA(20) : | 11.3 |
| MA(100) : | 16.31 |
MA(250) : | 15.77  |
|
| MACD | MACD : | -1.1 |
Signal : | -1.1 |
| %K %D | K(14,3) : | 6.7 |
D(3) : | 9.1 |
| RSI | RSI(14): 21.5 |
|||
| 52-week | High : | 23.29 | Low : | 8.89 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ MLTX ] has closed below the lower bollinger band by 5.2%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 22.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 10.22 - 10.28 | 10.28 - 10.32 |
| Low: | 9.29 - 9.37 | 9.37 - 9.43 |
| Close: | 9.44 - 9.55 | 9.55 - 9.64 |
MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, and both ankylosing spondylitis and radiographic axial spondyloarthritis. Established in 2021, MoonLake Immunotherapeutics is based in Zug, Switzerland.
Fri, 16 Oct 2026
MoonLake’s Psoriatic Arthritis Drug Shows Promise In Phase 3 Trial – Retail Shrugs Off Premarket Slide, Says ‘Pipeline Is Intact’ - Stocktwits
Fri, 16 Oct 2026
MLTX Stock Gains As Retail Eyes Buyout From Big Pharma, Upcoming Investor Day Event - Stocktwits
Thu, 15 Oct 2026
MLTX Stock Garners Retail Attention On Buyout Speculation, Positive Skin Condition Trial Data - Stocktwits
Wed, 14 Oct 2026
LifeSci Capital Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $33 - Moomoo
Mon, 05 Oct 2026
MoonLake Immunotherapeutics Could Win FDA Approval for Sonelokimab by Year-End 2027, Wedbush Says - Yahoo Finance
Fri, 02 Oct 2026
MoonLake Immunotherapeutics (MLTX) Receives a Rating Update from a Top Analyst - The Globe and Mail
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 85 (M) |
| Shares Float | 55 (M) |
| Held by Insiders | 8.1 (%) |
| Held by Institutions | 87.8 (%) |
| Shares Short | 8,050 (K) |
| Shares Short P.Month | 7,140 (K) |
| EPS | -3.83 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.11 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -32.5 % |
| Return on Equity (ttm) | -67.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.12 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -225 (M) |
| Levered Free Cash Flow | -132 (M) |
| PE Ratio | -2.5 |
| PEG Ratio | 0 |
| Price to Book value | 1.86 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.61 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|